Figure S1. Liver Blot Akt chemiluminescence MW 62kDa anti-Akt 1:300.



Control

Syrup control

Syrup group treated with metformin

Syrup group treated with *C. guatemalensis*

Syrup group treated with *E. cymosum*

Figure S2. Liver Blot Akt commasie.



Control

Syrup control

Syrup group treated with metformin

Syrup group treated with *C. guatemalensis*

Syrup group treated with *E. cymosum*

Figure S3. Representative samples Akt liver MW 62kDa anti-Akt 1:300.



Figure S4. Liver Blot pAkt1 (Ser 473) chemiluminescence MW 62kDa anti-pAkt 1:300.



Control

Syrup control

Syrup group treated with metformin

Syrup group treated with *C. guatemalensis*

Syrup group treated with *E. cymosum*

Figure S5. Liver Blot pAkt1 (Ser 473) commasie.



Control

Syrup control

Syrup group treated with metformin

Syrup group treated with *C. guatemalensis*

Syrup group treated with *E. cymosum*

Figure S6. Liver Representative samples pAkt 1 (Ser 473) MW 62kDa anti-pAkt1 1:300.



Figure S7. Liver Blot pAkt2 (Ser 474) chemiluminescence MW 62kDa anti-pAkt2 1:2000.



Control

Syrup control

Syrup group treated with metformin

Syrup group treated with *C. guatemalensis*

Syrup group treated with *E. cymosum*

Figure S8. Liver Blot pAkt2 (Ser 474) commasie.



Control

Syrup control

Syrup group treated with metformin

Syrup group treated with *C. guatemalensis*

Syrup group treated with *E. cymosum*

Figure S9. Liver Representative samples pAkt 2 (Ser 474) MW 62kDa anti-pAkt2 1:2000.



Figure S10. Muscle Blot Akt chemiluminescence MW 62kDa anti-Akt 1:1000.



Figure S11. Muscle Blot Akt commasie.



Figure S12. Representative samples Akt muscle MW 62kDa anti-Akt 1:1000.



Figure S13. Muscle Blot pAkt1 (Ser 473) chemiluminescence MW 62kDa anti-pAkt 1:500.



Control

Syrup control

Syrup group treated with metformin

Syrup group treated with *C. guatemalensis*

Syrup group treated with *E. cymosum*

Figure S14. Muscle Blot pAkt1 (Ser 473) commasie.



Control

Syrup control

Syrup group treated with metformin

Syrup group treated with *C. guatemalensis*

Syrup group treated with *E. cymosum*

Figure S15. Muscle Representative samples pAkt 1 (Ser 473) MW 62kDa anti-pAkt1 1:500.



Figure S16. Muscle Blot pAkt2 (Ser 474) chemiluminescence MW 62kDa anti-pAkt2 1:2000.



Control

Syrup control

Syrup group treated with metformin

Syrup group treated with *C. guatemalensis*

Syrup group treated with *E. cymosum*

Figure S17. Muscle Blot pAkt2 (Ser 474) commasie.



Control

Syrup control

Syrup group treated with metformin

Syrup group treated with *C. guatemalensis*

Syrup group treated with *E. cymosum*

Figure S18. Muscle Representative samples pAkt 2 (Ser 474) MW 62kDa anti-pAkt2 1:2000.

